Citigroup Inc. Raises Holdings in Inhibrx, Inc. - Defense World
| INBX Stock | USD 15.26 0.37 2.37% |
Slightly above 61% of Inhibrx's investor base is looking to short. The analysis of the overall investor sentiment regarding Inhibrx suggests that many traders are alarmed. Inhibrx's investing sentiment can be driven by a variety of factors including economic data, Inhibrx's earnings reports, geopolitical events, and overall market trends.
Inhibrx |
Citigroup Inc. Raises Holdings in Inhibrx, Inc. Defense World
Read at news.google.com
 |
Inhibrx Fundamental Analysis
We analyze Inhibrx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibrx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibrx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Inhibrx is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Inhibrx Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Inhibrx stock to make a market-neutral strategy. Peer analysis of Inhibrx could also be used in its relative valuation, which is a method of valuing Inhibrx by comparing valuation metrics with similar companies.
Peers
Inhibrx Related Equities
| GLUE | Monte Rosa | 13.72 | ||||
| OPT | Opthea | 10.81 | ||||
| LYEL | Lyell Immunopharma | 3.26 | ||||
| IKNA | Ikena Oncology | 2.37 | ||||
| STOK | Stoke Therapeutics | 1.68 | ||||
| HOWL | Werewolf Therapeutics | 1.52 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| DSGN | Design Therapeutics | 0.50 | ||||
| MRUS | Merus BV | 0.29 | ||||
| CELC | Celcuity LLC | 0.39 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.81 | ||||
| KRON | Kronos Bio | 1.04 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| VRDN | Viridian Therapeutics | 1.46 | ||||
| PTGX | Protagonist Therapeutics | 2.56 | ||||
| MLYS | Mineralys Therapeutics, | 2.59 | ||||
| ELVN | Enliven Therapeutics | 4.05 | ||||
| LRMR | Larimar Therapeutics | 4.67 |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.